Published in Medicine and Law Weekly, July 7th, 2006
This will be accomplished through a company to be called Accu-Strides, a 50:50 JVC. It is anticipated that the JVC will outsource from Strides an exclusive product pipeline of generic and ANDA products in finished dosage forms. It is also anticipated that the JVC will outsource from Accu-Break Pharmaceuticals sales, marketing and distribution capabilities...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.